Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) just picked up approval for its schizophrenia maintenance candidate. Here's all you need to know about the drug, and what it means for the company going forward. Imagine the trauma of you or a loved one losing touch with reality, feeling paranoid, experiencing auditory, visual,...
Celator Pharmaceuticals Inc (NASDAQ:CPXX) shares surged 71.59% to $30.08 on Tuesday after an acquisition announcement by Jazz Pharmaceuticals. Celator Pharmaceuticals Inc (NASDAQ:CPXX)  is an oncology-focused biopharmaceutical company engaged in developing products to improve patient outcomes in cancer. CombiPlex, its technology platform,  enables the design and evaluation of optimized combinations incorporating traditional...
VERITAS PHARMA INC COM NPV (OTCMKTS:VRTHF) is poised to grow exponentially in a nascent space - here's why. The medical marijuana industry is changing. As things stand, the vast majority of medical grade cannabis is dispensed through certified dispensaries, in states where cannabis is legalized for healthcare related use. Patients...
Minerva Neurosciences Inc (NASDAQ:NERV) shares jumped 13.09% on June 1 to $13.91 after the company shared positive top-line results in clinical trials for its antidepressant drug candidate. Minerva Neurosciences Inc (NASDAQ:NERV) is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of a portfolio of product candidates to treat...
Companies discussed: GlycoMimetics Inc (NASDAQ:GLYC), Cara Therapeutics Inc (NASDAQ:CARA), Advaxis, Inc (NASDAQ:ADXS) GlycoMimetics First up, GlycoMimetics Inc (NASDAQ:GLYC). GlycoMimetics just kicked off a phase 2 trial in patient with relapsed/refractory acute myeloid leukemia. The trial is the second part of a phase 1/2 in its lead oncology candidate, GMI1271, investigating the drug in combination...